LARGE1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Lastly, identifying drugs that upregulate surrogate proteins like ɛ-sarcoglycan in cases of α-sarcoglycanopthies, Integrin α7β1 in cases of γ-sarcoglycanopathies, or LARGE in cases of dystroglycanopathies, may also be of potential interest.